What is HC Wainwright’s Forecast for CervoMed Q2 Earnings?

CervoMed Inc. (NASDAQ:CRVO) – Research analysts at HC Wainwright decreased their Q2 2026 EPS estimates for shares of CervoMed in a research note issued on Tuesday, May 26th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.74) per share for the quarter, down from their previous estimate of ($0.70). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($2.87) per share. HC Wainwright also issued estimates for CervoMed’s Q3 2026 earnings at ($0.60) EPS, Q4 2026 earnings at ($0.65) EPS, FY2026 earnings at ($2.77) EPS, Q1 2027 earnings at ($0.71) EPS, Q2 2027 earnings at ($0.61) EPS, Q4 2027 earnings at ($0.61) EPS and FY2027 earnings at ($2.48) EPS.

CervoMed (NASDAQ:CRVO) last issued its quarterly earnings data on Monday, May 18th. The company reported ($0.86) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.04. CervoMed had a negative net margin of 672.80% and a negative return on equity of 136.08%.

Several other brokerages have also commented on CRVO. Chardan Capital upped their price objective on shares of CervoMed from $15.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, March 18th. Weiss Ratings restated a “sell (d-)” rating on shares of CervoMed in a report on Monday, April 20th. D. Boral Capital restated a “buy” rating and issued a $31.00 price objective on shares of CervoMed in a report on Wednesday, April 22nd. Roth Mkm set a $9.00 price objective on shares of CervoMed in a report on Monday, May 18th. Finally, upgraded shares of CervoMed to a “strong-buy” rating in a report on Tuesday, February 3rd. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.60.

CervoMed Stock Performance

Shares of CRVO stock opened at $3.04 on Thursday. The firm’s 50 day moving average price is $3.78 and its 200-day moving average price is $5.70. CervoMed has a one year low of $2.82 and a one year high of $13.13. The firm has a market cap of $28.15 million, a P/E ratio of -0.93 and a beta of -0.63.

Institutional Investors Weigh In On CervoMed

A number of hedge funds have recently added to or reduced their stakes in CRVO. Northwestern Mutual Wealth Management Co. lifted its holdings in CervoMed by 8,425,900.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 84,260 shares of the company’s stock worth $666,000 after buying an additional 84,259 shares in the last quarter. Jane Street Group LLC acquired a new stake in CervoMed during the 2nd quarter worth approximately $414,000. Renaissance Technologies LLC acquired a new stake in CervoMed during the 1st quarter worth approximately $252,000. Citadel Advisors LLC acquired a new stake in CervoMed during the 3rd quarter worth approximately $247,000. Finally, Savvy Advisors Inc. acquired a new stake in CervoMed during the 3rd quarter worth approximately $210,000. 25.15% of the stock is currently owned by institutional investors and hedge funds.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.